Coreg

Product manufactured by Glaxosmithkline Llc

Application Nr Approved Date Route Status External Links
NDA020297 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Coreg Is An Alpha-/beta-Adrenergic Blocking Agent Indicated For The Treatment Of: • Mild To Severe Chronic Heart Failure ( 1.1 ) • Left Ventricular Dysfunction Following Myocardial Infarction In Clinically Stable Patients ( 1.2 ) • Hypertension ( 1.3 ) 1.1 Heart Failure Coreg Is Indicated For The Treatment Of Mild-To-Severe Chronic Heart Failure Of Ischemic Or Cardiomyopathic Origin, Usually In Addition To Diuretics, Ace Inhibitors, And Digitalis, To Increase Survival And, Also, To Reduce The Risk Of Hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction Following Myocardial Infarction Coreg Is Indicated To Reduce Cardiovascular Mortality In Clinically Stable Patients Who Have Survived The Acute Phase Of A Myocardial Infarction And Have A Left Ventricular Ejection Fraction Of Less Than Or Equal To 40% (with Or Without Symptomatic Heart Failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Coreg Is Indicated For The Management Of Essential Hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It Can Be Used Alone Or In Combination With Other Antihypertensive Agents, Especially Thiazide-Type Diuretics [see Drug Interactions ( 7.2 )] .

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Carvedilol CARVEDILOL ZINC1530579

Comments